Charles River and Gazi University to offer plasmid DNA together

Introduction

Charles River Laboratories International, Inc., a well-known Contract Research Organisation (CRO), delivers fundamental services and products for government customers, academic space, biotech and pharmaceuticals to support and bolster development, manufacturing and drug discovery. The best-in-class research models and their close support to the valuable partners help innovation to uplift the treatment and introduce new approaches into the limelight.

A Turkish-based Gazi University Faculty of Medicine provides Turkish and English medical programs with the proof of education. These robust and knowledgeable programs bring awareness about public health and bolster the ethical development force. The university executes programs with the help of modern/advanced methods backed by a huge university hospital. This support brings clinical training into fruition.

Announcement

Charles and Gazi unite to offer plasmid DNA to in vitro efficacy studies and AAV production. Excited, Corporate Senior Vice President, Global Manufacturing, Charles River, Kerstin Dolph, said, “We are thrilled to form this powerful partnership with Gazi University. By accelerating cell and gene therapy, the CDMO specialist will allow the Faculty of Medicine to transition and test the excellent concepts in the genuine therapies.”

HTC and more

Hyperphosphatemic tumoral calcinosis (HTC) is a painful disorder also triggering high blood phosphate, where non-cancerous calcium phosphate is stored as soft tissues mainly on the surface of the shoulders, elbows and hips. This causes inflammation, movement problem and pain. This disorder is caused by some genetic condition; following this, Gazi University spotted GALNT3 as the qualified gene.

Regarding the same, Charles River will provide advance research oriented AAV plasmids along with the instant use and pre-manufactured option. This will help Gazi’s early-stage gene therapy programs. The plasmids are made of animal component free technique to mitigate cost and boost projects.

Gazi University been an academic figure that will wisely and smartly utilise the excellence of Charles River. This deal is a boon to the healthcare sector as a responsible AAV plasmid will heal HTC conditions with academic precision, and a qualified solution has always been acknowledged by the sector.

MD, Professor of Pediatrics and Head of the Department of Pediatric Genetics at Gazi University Faculty of Medicine, Prof. Fatih Ezgu, said, “We are excited about this partnership, which will bring CDMO expertise and academic innovation under one roof to leverage the establishment of advanced therapies. This collaboration is a benefit to our mission to develop groundbreaking, transformative therapies for rare diseases.”